Bayer Inks Renewable Energy Supply Deal with Wuppertaler Stadtwerke
Bayer AG has entered into a long-term agreement with Wuppertaler Stadtwerke (WSW), the public utility company of Wuppertal in North Rhein-Westphalia, Germany, to procure electricity from renewable sources. This partnership…
FDA Grants Approval to Alecensa as the Primary Adjuvant Therapy for Individuals with ALK-Positive Early-Stage Non-Small Cell Lung Cancer
Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) has announced that the U.S. Food and Drug Administration (FDA) has given approval for Alecensa® (alectinib), an anaplastic lymphoma kinase (ALK) inhibitor, to be…
Gepotidacin: Promising Oral Treatment for Uncomplicated Urogenital Gonorrhoea in Phase III Data
GSK plc (LSE/NYSE: GSK) has unveiled encouraging outcomes from the pivotal EAGLE-1 phase III trial concerning gepotidacin, a prospective first-in-class oral antibiotic offering a novel approach to combat uncomplicated urogenital…
Jumar Bioincubator: Pioneering Mini Brain & Lab-on-a-Chip Tech to Create Australia’s Next CSL
Australia’s Newest Biotech Incubator, Jumar Bioincubator, Opens with Ambitious Ventures Jumar Bioincubator has officially launched in Melbourne, welcoming its first cohort of 16 pioneering early-stage ventures. The event, graced by…
Vertex Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic Pain
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) has unveiled significant progress in its suzetrigine pain program, potentially introducing the first new class of medication for acute and neuropathic pain in over twenty…
Six-Year Efficacy of Novartis Kesimpta® in Relapsing MS Treatment-Naïve Patients
Novartis has revealed findings from the ALITHIOS open-label extension study, demonstrating the sustained efficacy of continuous Kesimpta® (ofatumumab) treatment for up to six years in individuals recently diagnosed with relapsing…
FDA Greenlights Alecensa by Roche for Early-Stage ALK-Positive Lung Cancer
Roche Receives FDA Approval for Alecensa as Adjuvant Therapy in ALK-Positive Early-Stage Lung Cancer Roche has announced that the U.S. Food and Drug Administration (FDA) has granted approval for Alecensa®…
Positive Outcomes in Giant Cell Arteritis Patients from Phase 3 SELECT-GCA Trial of Upadacitinib (RINVOQ®)
AbbVie (NYSE: ABBV) has announced encouraging findings from its Phase 3 trial, SELECT-GCA, showcasing positive top-line results. The trial, conducted across multiple centers, employed a randomized, double-blind, placebo-controlled design. It…
Building climate-resilient health clinics
On July 4, 2023, Lafayette, Louisiana experienced a seemingly typical Fourth of July, with kids playing soccer, families preparing for barbecues, and the familiar Louisiana heat enveloping the town. However,…
NEXT GENERATION PEPTIDE DRUGS FAVOR SYNTHETIC, NOT RECOMBINANT MANUFACTURING
Peptide manufacturing for commercial-scale production primarily employs two main methodologies: synthetic and recombinant. Each method presents unique advantages and challenges, crucial for stakeholders in the pharmaceutical industry to consider when…
Supporting Save the Children Finland: Orion’s Donation Ensures No Child or Young Person Copes Alone
The rising cost of living compounds the difficulties faced by low-income families with children, creating an urgent need for support, says Heidi Herranen, Coordinator of Save the Children Finland’s Fuel…
Cerevel Therapeutics Reports Favorable Topline Findings in Phase 3 Adjunctive Study of Tavapadon for Parkinson’s Disease Patients
Cerevel Therapeutics (Nasdaq: CERE) has released encouraging findings from its pivotal Phase 3 TEMPO-3 trial for tavapadon, a unique D1/D5 receptor partial agonist investigated as a once-daily treatment for Parkinson’s…